A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986454 in Healthy Participants

Bristol-Myers Squibb (BMS)

Status and phase

Completed

Phase 1

Conditions

Healthy Participants

Treatments

Drug: BMS-986454

Other: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

U1111-1270-3670 (Registry Identifier)

IM055-1001

Details and patient eligibility

About

The purpose of this study is to assess the safety and tolerability of BMS-986454 in healthy adult participants.

Enrollment

63 patients

Sex

All

Ages

18 to 55 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Male and female participants who are healthy as determined by the investigator based on review of medical history, physical examinations, 12-lead ECGs, and clinical laboratory tests obtained during the screening period.
Participant is willing and able to adhere to the study visit schedule and other protocol requirements.
A negative test for COVID-19, which will be performed in the manner mandated by the clinical site where this study is being conducted, at screening and admission.

Exclusion criteria

Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, 12-lead ECG, or clinical laboratory tests beyond what is consistent with a healthy population in the region in which the study is conducted.
Participant was exposed to an investigational drug (new chemical entity) within 30 days preceding the first dose administration, or 5 half-lives of that investigational drug, if known (whichever is longer).
Inability to be venipunctured or tolerate venous access.

Note: Other protocol-defined inclusion/exclusion criteria apply